Europe Endoscopic Hemostasis Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Бесплатный пример отчета Бесплатный пример отчета Узнать перед покупкой Узнать перед покупкой Купить сейчас Купить сейчас

Europe Endoscopic Hemostasis Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Europe Endoscopic Hemostasis Market, By Product Type (Mechanical Hemostasis Devices, Thermal Devices, Topical Agents and Injectables, and Others), Procedure (Upper Gastrointestinal Endoscopy, Lower Gastrointestinal Endoscopy, Bronchoscopic Hemostasis, and Others), Application (Gastrointestinal Bleeding, Non-Gastrointestinal Bleeding, Trauma Management, and Others), End User (Hospitals, Ambulatory Surgery Centers, Specialty Clinics, and Others), Distribution Channel (Direct Sales and Indirect Sales) - Industry Trends and Forecast to 2033

  • Healthcare
  • Feb 2026
  • Europe
  • 350 Pages
  • Количество таблиц: 393
  • Количество рисунков: 39
  • Author : Sachin Pawar

Europe Endoscopic Hemostasis Market

Размер рынка в млрд долларов США

CAGR :  % Diagram

Chart Image USD 675.69 Million USD 1,183.22 Million 2025 2033
Diagram Прогнозируемый период
2026 –2033
Diagram Размер рынка (базовый год)
USD 675.69 Million
Diagram Размер рынка (прогнозируемый год)
USD 1,183.22 Million
Diagram CAGR
%
Diagram Основные игроки рынка
  • Olympus Corporation
  • Boston Scientific Corporation
  • CONMED Corporation
  • Medtronic
  • Cook Medical

Europe Endoscopic Hemostasis Market, By Product Type (Mechanical Hemostasis Devices, Thermal Devices, Topical Agents and Injectables, and Others), Procedure (Upper Gastrointestinal Endoscopy, Lower Gastrointestinal Endoscopy, Bronchoscopic Hemostasis, and Others), Application (Gastrointestinal Bleeding, Non-Gastrointestinal Bleeding, Trauma Management, and Others), End User (Hospitals, Ambulatory Surgery Centers, Specialty Clinics, and Others), Distribution Channel (Direct Sales and Indirect Sales) - Industry Trends and Forecast to 2033

Europe Endoscopic Hemostasis Market Size

  • The Europe endoscopic hemostasis market is expected to reach USD 1,183.22 million by 2033 from USD 675.69 million in 2025, growing with a substantial CAGR of 7.7% in the forecast period of 2026 to 2033
  • The Europe endoscopic hemostasis market is witnessing steady and robust growth, driven by the rising prevalence of gastrointestinal disorders, increasing incidence of colorectal cancer, peptic ulcers, and gastrointestinal bleeding, and the growing adoption of minimally invasive endoscopic procedures across the region..
  • Market growth is further supported by stringent clinical guidelines, a strong focus on patient safety and procedural efficacy, and rising demand for advanced hemostatic technologies that improve procedural outcomes and reduce complication rates. Continuous advancements in endoscopic device design, including improved clips, coagulation systems, sprays, and combination therapies, are enhancing precision, ease of use, and clinical effectiveness.

Europe Endoscopic Hemostasis Market Analysis

  • Endoscopic Hemostasis products are becoming increasingly critical across the Europe healthcare ecosystem, enabling clinicians to effectively manage gastrointestinal bleeding during diagnostic and therapeutic endoscopic procedures. These devices play a vital role in improving procedural safety, clinical outcomes, and patient recovery by ensuring rapid and reliable bleeding control. Endoscopic hemostasis solutions are widely used across key clinical settings, including hospitals, specialty clinics, and ambulatory surgical centers, for applications such as peptic ulcer bleeding, colorectal procedures, post-polypectomy bleeding, and tumor-related hemorrhage.
  • Expanding healthcare infrastructure, rising volumes of endoscopic procedures, and increasing adoption of minimally invasive treatment approaches are fueling strong demand for endoscopic hemostasis devices in Europe. Healthcare providers are increasingly incorporating advanced hemostatic technologies to improve procedural efficiency, reduce complication rates, shorten hospital stays, and enhance overall patient outcomes, thereby supporting sustained market growth.
  • Additionally, stringent clinical guidelines, increasing emphasis on patient safety, and growing regulatory scrutiny are accelerating the adoption of advanced and clinically proven endoscopic hemostasis solutions. Medical device manufacturers are investing heavily in R&D to develop innovative products that offer improved precision, ease of use, and compatibility with modern endoscopic platforms, while meeting evolving regulatory standards and clinical performance requirements.
  • Germany is projected to lead the Europe endoscopic hemostasis market in 2026, accounting for 15.89% of the regional market share. This leadership is supported by the country’s well-established healthcare infrastructure, high volume of endoscopic procedures, strong adoption of advanced medical technologies, and presence of leading medical device manufacturers. Favorable reimbursement frameworks, a skilled clinical workforce, and continuous investments in healthcare innovation further strengthen Germany’s dominant position within the European market.
  • Denmark is the fastest-growing country in the Europe endoscopic hemostasis market, supported by early adoption of digital health and advanced endoscopy platforms, strong integration of AI-assisted diagnostics and image-guided endoscopic procedures, and a high level of clinical research participation in gastrointestinal and interventional endoscopy. The country’s well-structured referral pathways, emphasis on day-care and outpatient endoscopic treatments, and rapid commercial uptake of next-generation hemostatic devices by clinicians further accelerate procedural volumes. In addition, collaborations between hospitals, academic institutions, and medical device manufacturers, along with streamlined regulatory approval timelines for innovative technologies, continue to position Denmark as a leading early-adopter market, driving faster growth compared to other European countries.
  • The Mechanical Hemostasis Devices segment is dominating the Europe Endoscopic Hemostasis Market, accounting for 43.86% market share in 2025. This dominance is driven by the widespread clinical adoption of endoscopic clips and band ligation devices due to their proven efficacy, ease of deployment, cost-effectiveness, and suitability for a broad range of gastrointestinal bleeding indications. Their strong safety profile and compatibility with standard endoscopic procedures continue to support sustained demand across healthcare settings.

Europe Endoscopic Hemostasis Market z

Report Scope and Europe Endoscopic Hemostasis Market Segmentation    

Attributes

Europe Endoscopic Hemostasis Market Insights

Segments Covered

  • By Product Type: Mechanical Hemostasis Devices, Thermal Devices, Topical Agents and Injectables and Others.
  • By Procedure: Upper Gastrointestinal Endoscopy, Lower Gastrointestinal Endoscopy, Bronchoscopic Hemostasis and Others
  • By Application: Gastrointestinal Bleeding, Non-Gastrointestinal Bleeding, Trauma Management and Others
  • By End User: Hospitals, Ambulatory Surgery Centers, Specialty Clinics and Others
  • By Distribution Channel: Direct Sales and Indirect Sales

Countries Covered

Europe

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Switzerland
  • Sweden
  • Denmark
  • Norway
  • Finland
  • Russia
  • Turkey
  • Rest of Europe

Key Market Players

  • Micro-Tech Endoscopy (China)
  • Taewoong Medical Co., Ltd. (South Korea)
  • Ovesco Endoscopy AG (Germany)
  • Apollo Endosurgery, Inc. (U.S.)
  • Argon Medical Devices, Inc. (U.S.)
  • Olympus Corporation (Japan)
  • Boston Scientific Corporation (U.S.)
  • CONMED Corporation (U.S.)
  • Medtronic (Ireland)
  • Cook (U.S.)
  • ERBE Elektromedizin GmbH (Germany)
  • Karl Storz SE & Co. KG (Germany)
  • Pentax Medical (Japan)
  • Endoskopie Technik Gerhard (Germany)
  • Merit Medical Systems, Inc. (U.S.)
  • Diversatek, Inc. (U.S.)
  • STERIS plc (U.K.)
  • B. Braun SE (Germany)
  • Duomed Group (Belgium)

Market Opportunities

  • Technological advancements in hemostasis devices
  • Expansion in emerging markets (Europe, Latin America)
  • Growing adoption of home-based and capsule endoscopy solutions

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include Vendor Selection Criteria, Technological Advancement, Patent Analysis, regulatory framework, Innovation Tracker and strategic analysis Tariffs and Impact on the market.

Europe Endoscopic Hemostasis Market Trends

Increasing Adoption of Advanced Minimally Invasive Endoscopic Hemostasis Technologies

  • The steady expansion of endoscopic and minimally invasive procedures across Europe is a major factor driving the increased adoption of endoscopic hemostasis devices. As the incidence of gastrointestinal bleeding, colorectal disorders, and related conditions continues to rise, healthcare providers increasingly rely on advanced hemostasis solutions to ensure effective bleeding control, procedural safety, and improved patient outcomes across high-volume clinical environments.
  • Endoscopic hemostasis devices play a critical role in ensuring clinical efficacy, patient safety, and procedural reliability throughout diagnostic and therapeutic endoscopy. By enabling rapid bleeding control, reducing complication risks, and supporting minimally invasive treatment approaches, these devices help optimize procedural workflows while improving recovery times and overall quality of care across healthcare facilities.
  • The growing adoption of advanced endoscopic technologies, including high-definition imaging, therapeutic endoscopy, and combination hemostasis techniques, has increased demand for high-performance hemostatic solutions. Innovations in mechanical clips, thermal coagulation systems, injection therapies, and topical hemostatic agents are enhancing procedural precision, treatment success rates, and clinician confidence while supporting evolving clinical practices.
  • Healthcare providers across the care continuum are increasingly adopting endoscopic hemostasis devices to meet rising regulatory, safety, and clinical performance standards. Stringent clinical guidelines, growing emphasis on patient safety and outcome-based care, and increasing demand for minimally invasive interventions are encouraging hospitals and clinics to integrate advanced hemostasis technologies that ensure consistency, compliance, and high-quality care delivery.
  • Overall, the expanding scale of endoscopic procedures, clinical innovation, and healthcare infrastructure development positions endoscopic hemostasis devices as an essential component of modern gastrointestinal care. These solutions support procedural efficiency, patient safety, regulatory compliance, and sustainable growth across Europe’s evolving endoscopy landscape, making this insight readily reusable across regions by adapting healthcare system dynamics and adoption patterns.

Europe Endoscopic Hemostasis Market Dynamics

Driver

Rise in Gastrointestinal Bleeding Cases

  • The rising incidence of gastrointestinal bleeding has been established as a foundational force propelling growth in the global endoscopic hemostasis market. As the prevalence of upper and lower gastrointestinal bleeding conditions increases worldwide, demand for minimally invasive, endoscopy-based therapeutic interventions has been intensified. Endoscopic hemostasis offers critical clinical advantages, including rapid bleeding control, reduced need for surgical intervention, lower transfusion requirements, and shorter hospital stays, thereby positioning it as a first-line treatment modality in acute and chronic gastrointestinal bleeding management. Consequently, the escalation in gastrointestinal bleeding cases—driven by aging populations, higher prevalence of liver disease, anticoagulant use, and delayed care access during systemic healthcare disruptions—has translated into higher procedural volumes and broader adoption of advanced endoscopic hemostasis devices across hospitals and endoscopy centers globally.
    • For instances,
  • In September 2021, Medscape reported that upper gastrointestinal bleeding occurred at an incidence of approximately 100 cases per 100,000 population annually and remained one of the most common causes of emergency hospital admissions, underscoring a persistently high disease burden requiring endoscopic intervention.
  • In June2023, Gastroenterology Research journal reported that mortality related to upper gastrointestinal bleeding in the U.S. increased between 2012 and 2021, with steeper increases observed toward the later years, indicating worsening clinical outcomes and intensified treatment requirements.
  • In June 2023, StatPearls Publishing stated that gastrointestinal bleeding continues to represent a frequent global medical emergency, with urgent endoscopic diagnosis and hemostatic treatment remaining critical to reducing mortality and morbidity.
  • In January 2025, the Journal of Clinical Medicine reported that patients with advanced liver disease exhibited significantly higher incidence of massive gastrointestinal bleeding episodes, reinforcing the link between chronic disease prevalence and increased need for endoscopic hemostasis.
  • In September 2025, PubMed Central highlighted that upper gastrointestinal bleeding remained a life-threatening complication among chronic liver disease populations, sustaining elevated demand for endoscopic therapeutic procedures.
  • The global escalation in gastrointestinal bleeding incidence is being firmly established as a permanent structural growth engine for the endoscopic hemostasis market. The continuous rise in acute bleeding events, combined with expanding populations affected by chronic liver disease, antithrombotic medication use, and age-related gastrointestinal pathology, is creating a sustained and non-cyclical requirement for endoscopic bleeding control. As clinical guidelines increasingly prioritize endoscopic therapy as first-line management, reliance on hemostasis technologies for emergency intervention, recurrence prevention, and complication management is being structurally reinforced. Furthermore, improving survival rates are extending patient monitoring and repeat intervention cycles, thereby multiplying lifetime procedural demand. This dynamic is anchoring endoscopic hemostasis adoption closely to global epidemiological trends, positioning this driver as a long-term foundational pillar for market expansion across developed and emerging healthcare systems.

Restraint/Challenge

High Cost and Technical Complexity of Endoscopic Hemostasis Devices

  • Despite growing clinical adoption, the Europe endoscopic hemostasis market continues to face structural restraint due to the high cost and technical complexity of advanced endoscopic hemostasis devices. These technologies often require significant upfront capital investment for equipment procurement, continuous expenditure on consumables, and specialized maintenance. In addition, effective use of hemostatic endoscopic devices demands advanced physician training, skilled support staff, and sophisticated hospital infrastructure, limiting adoption in cost-sensitive healthcare systems. Public hospitals in low- and middle-income countries, and even budget-constrained facilities in developed regions, frequently encounter barriers related to affordability, reimbursement gaps, and workforce readiness. As a result, uneven access and slower penetration of advanced endoscopic hemostasis technologies persist, constraining broader market expansion.
    • For Instance,
  • In November 2022, according to the high cost of gastrointestinal endoscopy procedures and equipment is a major restraint. For example, TNE costs Euro 125.90 per procedure, while oral endoscopy costs Euro 184.10 and MACE costs Euro 407.10. Additionally, equipment maintenance and reprocessing add to the cost, with flexible endoscopes costing around Euro 79,330, making procedures expensive overall.
  • In June 2024, Science direct highlighted that the high cost of gastrointestinal endoscopy is exacerbated in low-income and middle-income countries (LICs and LMICs) due to the lack of local maintenance and repair facilities. Scopes requiring repairs must be shipped abroad, incurring significant costs and delays. Additionally, cheaper second-hand and Chinese-manufactured endoscopes often lack adequate service and maintenance support.
  • In October 2025, BMJ Open Gastroenterology published a micro-costing study showing that in a UK National Health Service hospital, the total per-procedure cost of reusable gastrointestinal endoscopes was an estimated GBP107.34, with capital and maintenance costs as major cost drivers, highlighting economic barriers to wide adoption of endoscopic equipment in public health settings.
  • In August 2024, a ScienceDirect narrative review reported that purchase, maintenance, and associated logistics costs of endoscopy equipment remain a major barrier to developing and sustaining endoscopy services in low- and middle-income countries, due to high device cost and lack of infrastructure.
  • In February 2025, as per science direct the high cost of gastrointestinal endoscopy is evident in various studies, especially for screening and surveillance. For instance, while general population screenings may not be cost-effective in Western regions, targeted surveillance for high-risk groups, such as those with gastric intestinal metaplasia, can still be cost-effective, with ICERs ranging from USD 20,739.1 to 98,402.2 per QALY.
  • The compiled evidence clearly indicates that the high cost and technical complexity associated with gastrointestinal endoscopy and endoscopic hemostasis devices represent a persistent restraint on market growth. Substantial capital investment for equipment procurement, elevated per-procedure costs, and ongoing expenses related to maintenance, reprocessing, and repair significantly increase the overall cost burden on healthcare systems. These challenges are further intensified in low- and middle-income regions where limited technical infrastructure and lack of local servicing capabilities delay adoption and restrict procedural capacity. Even in developed healthcare systems, cost-effectiveness considerations influence screening strategies and limit widespread implementation. Collectively, these economic and operational constraints slow penetration of advanced endoscopic hemostasis technologies, reinforcing affordability and technical complexity as structural barriers to broader market expansion

Europe Endoscopic Hemostasis Market Scope

The Europe endoscopic hemostasis market is categorized into five key segments: product type, procedure, application, end user, and distribution channel.

  • By product type

On the basis of product type, the Europe endoscopic hemostasis market is segmented into mechanical hemostasis devices, thermal devices, topical agents and injectables, and others. In 2026, the mechanical hemostasis devices segment is projected to dominate the Europe endoscopic hemostasis market with the largest market share of 43.89%, owing to its widespread clinical preference for achieving immediate, controlled, and durable bleeding cessation during endoscopic interventions. Mechanical solutions such as clips and banding devices are routinely favored for their ability to provide precise vessel closure without inducing thermal tissue damage, thereby lowering rebleeding rates and post-procedure complications. Their applicability across a broad spectrum of bleeding scenarios, including peptic ulcers, variceal hemorrhage, and post-polypectomy bleeding, has resulted in consistently high utilization in both emergency and elective endoscopic settings. The strong reliance on mechanical hemostasis as a first-line therapeutic approach underscores its substantial contribution to overall market revenues and reinforces its dominant position within the product type landscape throughout the forecast period.

The topical agents and injectables segment is the fastest-growing segment in the Europe endoscopic hemostasis market, registering a CAGR of 8.1%. This growth is primarily driven by the rising incidence of gastrointestinal (GI) bleeding disorders, increasing adoption of minimally invasive endoscopic procedures, and the clinical preference for fast-acting, easy-to-apply hemostatic solutions during emergency and elective interventions.

  • By procedure

On the basis of procedure, the market is segmented into upper gastrointestinal endoscopy, lower gastrointestinal endoscopy, bronchoscopic hemostasis, and others. In 2026, the upper gastrointestinal endoscopy segment is projected to dominate the Europe endoscopic hemostasis market with a market share of 43.62%, due to its extensive clinical adoption as the frontline procedural approach for managing acute and recurrent gastrointestinal bleeding. Upper GI endoscopy is widely relied upon for the diagnosis and immediate therapeutic control of bleeding ulcers, variceal hemorrhage, and Dieulafoy lesions, where rapid hemostatic intervention is clinically critical. The high procedural frequency in emergency departments and tertiary-care hospitals, combined with strong guideline support for early endoscopic intervention, is expected to sustain its leading market position. Its continued dominance is reflected in its substantial market share and steady growth trajectory through 2033, indicating persistent demand across both developed and emerging healthcare systems.

The lower gastrointestinal endoscopy segment is the fastest-growing segment in the Europe endoscopic hemostasis market, registering a CAGR of 8.1%. This growth is driven by the rising prevalence of lower gastrointestinal bleeding conditions, including colorectal cancer, inflammatory bowel disease, diverticular disease, and hemorrhoidal bleeding, along with increasing adoption of screening and diagnostic colonoscopy procedures across Europe.

  • By application

On the basis of application, the market is segmented into gastrointestinal bleeding, non-gastrointestinal bleeding, trauma management, and others. In 2026, the gastrointestinal bleeding segment is projected to dominate the Europe endoscopic hemostasis market with a market share of 71.57%, owing to the high global prevalence of peptic ulcers, esophageal varices, and colorectal malignancies requiring endoscopic bleeding control. Gastrointestinal bleeding remains the most common indication for endoscopic hemostasis procedures, driving consistent utilization of mechanical, thermal, and topical hemostatic solutions across hospital and ambulatory care settings. The critical need for rapid bleeding control to reduce morbidity, hospital length of stay, and mortality is expected to reinforce sustained demand within this application segment. Its large share of total market value highlights the central role of gastrointestinal indications in shaping overall market dynamics during the forecast period.

The trauma management segment is the fastest-growing segment in the Europe endoscopic hemostasis market, registering a CAGR of 8.3%. This growth is driven by the increasing incidence of traumatic injuries, including abdominal trauma, accidental injuries, and emergency gastrointestinal bleeding cases, along with the rising preference for minimally invasive endoscopic interventions to achieve rapid bleeding control.

  • By end user

On the basis of end user, the market is segmented into hospitals, ambulatory surgery centers, specialty clinics, and others. In 2026, the hospitals segment is projected to dominate the Europe endoscopic hemostasis market with the largest market share of 52.69%, due to the concentration of advanced endoscopy infrastructure, skilled gastroenterologists, and emergency care capabilities within hospital settings. Complex bleeding cases, including severe upper and lower gastrointestinal hemorrhage, are predominantly managed in public and private hospitals where comprehensive diagnostic and interventional resources are available. Higher patient inflow, greater procedural volumes, and established procurement frameworks further strengthen hospital demand for endoscopic hemostasis devices and consumables. This structural dependence on hospital-based care is expected to maintain the segment’s leading position through 2033 despite gradual growth in outpatient settings.

The ambulatory surgery centers segment is the fastest-growing segment in the Europe endoscopic hemostasis market, registering a CAGR of 8.1%. This growth is driven by the shift of endoscopic procedures from hospitals to outpatient settings, increasing demand for cost-effective and minimally invasive interventions, and the rising adoption of same-day diagnostic and therapeutic endoscopy across Europe.

  • By distribution channel

On the basis of distribution channel, the market is segmented into direct sales and indirect sales, with indirect sales further segmented into online and offline channels. In 2026, the indirect sales segment is projected to dominate the Europe endoscopic hemostasis market with the largest market share of 58.48% as procurement is largely conducted through distributors, group purchasing organizations, and regional medical supply networks. Indirect channels are widely preferred due to their ability to offer bundled products, inventory management support, and broader geographic reach, particularly in emerging markets and decentralized healthcare systems. Hospitals and ambulatory centers frequently rely on distributor-led sourcing to ensure consistent availability of critical hemostasis devices while optimizing procurement costs. This distribution structure is expected to continue driving higher adoption of indirect sales channels throughout the forecast period.

The indirect sales segment is the fastest-growing distribution channel in the Europe endoscopic hemostasis market, registering a CAGR of 7.9%. This growth is driven by the expanding role of third-party distributors, group purchasing organizations (GPOs), and regional medical device suppliers in improving market access across diverse European healthcare systems.

Europe Endoscopic Hemostasis Market Regional Analysis

  • Germany represents one of the most important markets for endoscopic hemostasis devices, supported by its advanced healthcare infrastructure, strong medical device manufacturing base, and high adoption of minimally invasive endoscopic procedures. Continuous clinical innovation in gastroenterology, a high volume of diagnostic and therapeutic endoscopies, and strict clinical and regulatory standards are driving steady adoption of advanced mechanical, thermal, and topical hemostasis solutions across hospitals and specialty care centers.
  • The U.K. is witnessing growing demand for endoscopic hemostasis technologies as increasing prevalence of gastrointestinal disorders, an aging population, and rising emphasis on minimally invasive treatment approaches reshape clinical practice. Healthcare providers are increasingly focused on improving patient safety, reducing procedure-related complications, and enhancing clinical efficiency, which is accelerating the adoption of reliable and cost-effective hemostasis devices across public and private healthcare settings.
  • France continues to emerge as a key growth hub for the endoscopic hemostasis market, driven by strong clinical expertise in gastroenterology, expanding access to advanced endoscopic services, and increasing focus on patient-centered and outcome-driven care. The country’s emphasis on clinical quality, safety, and technological innovation is encouraging healthcare institutions to adopt advanced hemostasis solutions that improve procedural outcomes, support minimally invasive interventions, and comply with evolving regulatory and healthcare standards.

Germany Endoscopic Hemostasis Market Insight

The Germany Endoscopic Hemostasis Market is gaining strong traction due to the country’s high volume of gastrointestinal endoscopic procedures and early adoption of advanced therapeutic endoscopy techniques. German hospitals and specialty clinics place strong emphasis on clinical precision, procedural reliability, and evidence-based device selection, driving consistent demand for high-performance mechanical and energy-based hemostasis solutions. In addition, the presence of leading medical device manufacturers, well-established clinical training programs, and strict regulatory and quality standards is fostering rapid uptake of technologically advanced hemostasis devices. Germany’s focus on procedural standardization, patient safety, and outcome optimization reinforces its position as a technology-led and innovation-driven market within Europe.

U.K. Endoscopic Hemostasis Market Insight

The U.K. Endoscopic Hemostasis Market continues to expand as healthcare providers prioritize minimally invasive treatment pathways, efficiency in endoscopy units, and reduction of procedure-related complications. Rising incidence of gastrointestinal bleeding conditions, combined with increasing demand on NHS endoscopy services, is accelerating adoption of cost-effective, easy-to-use hemostasis devices that support high procedural throughput. Strong emphasis on clinical guidelines, value-based care, and standardized treatment protocols is shaping purchasing decisions, while growing use of ambulatory and day-care endoscopy settings is further supporting demand. These factors collectively position the U.K. market as one driven by access, efficiency, and scalable clinical adoption rather than device manufacturing concentration.

Europe Endoscopic Hemostasis Market Share

The Specialty Food Ingredients industry is primarily led by well-established companies, including:

  • Micro-Tech Endoscopy (China)
  • Taewoong Medical Co., Ltd. (South Korea)
  • Ovesco Endoscopy AG (Germany)
  • Apollo Endosurgery, Inc. (U.S.)
  • Argon Medical Devices, Inc. (U.S.)
  • Olympus Corporation (Japan)
  • Boston Scientific Corporation (U.S.)
  • CONMED Corporation (U.S.)
  • Medtronic (Ireland)
  • Cook (U.S.)
  • ERBE Elektromedizin GmbH (Germany)
  • Karl Storz SE & Co. KG (Germany)
  • Pentax Medical (Japan)
  • Endoskopie Technik Gerhard (Germany)
  • Merit Medical Systems, Inc. (U.S.)
  • Diversatek, Inc. (U.S.)
  • STERIS plc (U.K.)
  • B. Braun SE (Germany)
  • Duomed Group (Belgium)

Latest Developments in the Europe endoscopic hemostasis market

  • In December 2025, Olympus tripled its corporate venture capital fund commitment by launching Olympus Innovation Ventures Fund II with an additional $150 million to invest in MedTech startups focused on endoscopy, diagnostics, digital health, and related innovation fields to reinforce long-term growth and technological leadership.
  • In October 2025, Boston Scientific announced an agreement to acquire Nalu Medical, Inc., a privately held medical device company focused on implantable neurostimulation technologies for chronic pain. The acquisition was positioned to strengthen Boston Scientific’s neuromodulation portfolio, accelerate innovation in pain management, and expand treatment options for patients with chronic pain conditions.
  • In October 2025, CONMED Corporation announced a strategic exit from its gastroenterology business, divesting its GI product lines and related assets as part of a portfolio realignment to concentrate on core surgical and orthopaedic solutions. The move was positioned to streamline the company’s product focus, sharpen investment in high-growth procedural areas, and improve long-term revenue and margin profiles by reallocating resources toward CONMED’s flagship device platforms and emerging technologies.
  • In August 2025, the U.S. Food and Drug Administration (FDA) approved the first-of-its-kind IDE clinical study of Cook Medical’s ADVANCE EVERO 18 everolimus-coated PTA balloon catheter, enabling evaluation of its safety and effectiveness in treating symptomatic peripheral arterial disease. The decision marked a milestone for drug-coated balloon technology, supporting Cook’s advancement of next-generation endovascular therapies aimed at reducing restenosis and improving long-term vessel patency in patients with lower-extremity arterial disease..
  • In July, ESGE guidelines on topical hemostatic agents reported Ankaferd Blood Stopper with 73%-100% hemostasis rates for GI bleeding sources such as peptic ulcers and malignancies in endoscopic use..


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE ENDOSCOPIC HEMOSTASIS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7 MULTIVARIATE MODELLING

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END-USER COVERAGE GRID

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTERS FIVE FORCES ANALYSIS

4.2 BRAND OUTLOOK

4.2.1 BRAND COMPARATIVE ANALYSIS OF KEY EUROPE PLAYERS

4.2.1.1 BRAND COMPARATIVE NARRATIVE (ANALYTICAL OVERVIEW)

4.2.2 PRODUCT VS BRAND OVERVIEW — EUROPE ENDOSCOPIC HEMOSTASIS MARKET

4.2.2.1 PRODUCT OVERVIEW — ENDOSCOPIC HEMOSTASIS DEVICES

4.2.2.2 BRAND OVERVIEW — INFLUENCE ON EUROPE CLINICAL ADOPTION

4.3 CONSUMER BUYING BEHAVIOUR

4.3.1 CLINICAL EFFECTIVENESS AND PATIENT OUTCOMES

4.3.2 COST AND VALUE CONSIDERATIONS

4.3.3 COMPATIBILITY AND INTEGRATION

4.3.4 TRAINING REQUIREMENTS AND EASE OF USE

4.3.5 REIMBURSEMENT AND HEALTHCARE POLICY ALIGNMENT

4.3.6 PROCUREMENT PROCESSES AND BULK AGREEMENTS

4.3.7 INFLUENCE OF CLINICAL STAKEHOLDERS

4.3.8 TRENDS IN BUYER BEHAVIOUR

4.3.9 CONCLUSION

4.4 PATENT ANALYSIS

4.4.1 PATENT QUALITY AND STRENGTH – EUROPE ENDOSCOPIC HEMOSTASIS MARKET

4.4.2 COUNTRY PATENT LANDSCAPE

4.4.3 IP STRATEGY AND MANAGEMENT

4.4.4 LICENSING AND COLLABORATION

4.5 RAW MATERIAL COVERAGE

4.5.1 METALLIC COMPONENTS AND ALLOY SYSTEMS

4.5.2 POLYMERIC AND SYNTHETIC MATERIALS

4.5.3 NATURAL AND BIOCOMPATIBLE MATERIALS

4.5.4 ELECTRICAL AND THERMAL MATERIAL SYSTEMS

4.5.5 EXPENDABLE ACCESSORIES AND SINGLE-USE MATERIALS

4.6 TECHNOLOGICAL ADVANCEMENTS IN EUROPE ENDOSCOPIC HEMOSTASIS MARKET

4.6.1 ENHANCED MECHANICAL HEMOSTASIS TOOLS

4.6.2 ADVANCED THERMAL COAGULATION AND ENERGY-BASED SYSTEMS

4.6.3 NOVEL TOPICAL HEMOSTATIC AGENTS

4.6.4 INTEGRATION WITH ADJUNCTIVE DIAGNOSTIC TECHNOLOGIES

4.6.5 DEVELOPMENT OF MULTIFUNCTIONAL AND COMBINATION DEVICES

4.6.6 IMPROVED USER ERGONOMICS AND DEVICE DEPLOYMENT SYSTEMS

4.6.7 CONCLUSION

4.7 VALUE CHAIN ANALYSIS

4.7.1 OVERVIEW

4.7.2 RAW MATERIALS & COMPONENTS

4.7.3 DEVICE DESIGN, R&D & MANUFACTURING

4.7.4 PROCESSING, FINISHING & STERILIZATION

4.7.5 PACKAGING & LABELING

4.7.6 LOGISTICS, DISTRIBUTION & COMMERCIALIZATION

4.7.7 CONCLUSION

4.8 VENDOR SELECTION CRITERIA

4.8.1 CLINICAL PERFORMANCE

4.8.2 REGULATORY COMPLIANCE AND APPROVALS

4.8.3 COST AND TOTAL VALUE PROPOSITION

4.8.4 SUPPLY CHAIN ROBUSTNESS AND LOGISTICS

4.8.5 SUPPORT, TRAINING AND CLINICAL EDUCATION

4.8.6 QUALITY SYSTEMS AND REPROCESSING GUIDANCE

4.8.7 REPUTATION, PEER ACCEPTANCE AND POST-MARKET PERFORMANCE

4.8.8 INNOVATION AND FUTURE-READINESS

4.9 COMPANY EVALUATION QUADRANT

4.1 PROFIT MARGIN SCENARIO

4.10.1 MARGIN IMPROVEMENT DRIVERS

4.10.2 COST PRESSURE

4.10.3 REGIONAL VARIATIONS

4.10.4 FUTURE SCENARIOS

4.11 CLIMATE CHANGE SCENARIO

4.11.1 ENVIRONMENTAL CONCERNS

4.11.2 INDUSTRY RESPONSE

4.11.3 GOVERNMENT’S ROLE

4.11.4 ANALYST RECOMMENDATIONS

4.12 INNOVATION TRACKER AND STRATEGIC ANALYSIS

4.12.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

4.12.1.1 JOINT VENTURES

4.12.1.2 MERGERS AND ACQUISITIONS

4.12.1.3 LICENSING AND PARTNERSHIP

4.12.1.4 TECHNOLOGY COLLABORATIONS

4.12.2 STRATEGIC DIVESTMENTS

4.12.3 STAGE OF DEVELOPMENT

4.12.4 TIMELINES AND MILESTONES

4.12.5 INNOVATION STRATEGIES AND METHODOLOGIES

4.12.6 RISK ASSESSMENT AND MITIGATION

4.12.7 FUTURE OUTLOOK

4.13 PRICING ANALYSIS

4.13.1 HEMOSTATIC CLIPS AND FORCEPS PRICING

4.13.2 BANDING AND COAGULATION DEVICES

4.13.3 REGULATORY AND REIMBURSEMENT IMPACT

4.14 SUPPLY CHAIN ANALYSIS

4.14.1 OVERVIEW

4.14.2 LOGISTIC COST SCENARIO

4.14.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS

4.14.4 CONCLUSION

5 TARIFFS & IMPACT ON THE MARKET

5.1 OVERVIEW

5.2 CURRENT TARIFF RATE (S) IN TOP-5 COUNTRY MARKETS

5.3 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE

5.4 VENDOR SELECTION CRITERIA

5.5 IMPACT ON SUPPLY CHAIN

5.5.1 RAW MATERIAL PROCUREMENT

5.5.2 MANUFACTURING AND PRODUCTION

5.5.3 LOGISTICS AND DISTRIBUTION

5.5.4 PRICE PITCHING AND POSITION OF MARKET

5.6 INDUSTRY PARTICIPANTS: PROACTIVE MOVES

5.6.1 SUPPLY CHAIN OPTIMIZATION

5.6.2 JOINT VENTURE ESTABLISHMENTS

5.7 IMPACT ON PRICES

5.8 REGULATORY INCLINATION

5.8.1 GEOPOLITICAL SITUATION

5.8.2 TRADE PARTNERSHIPS BETWEEN THE COUNTRIES

5.8.2.1 FREE TRADE AGREEMENTS

5.8.2.2 ALLIANCES ESTABLISHMENTS

5.8.3 STATUS ACCREDITATION (INCLUDING MFTN)

5.8.4 DOMESTIC COURSE OF CORRECTION

5.8.4.1 INCENTIVE SCHEMES TO BOOST PRODUCTION OUTPUTS

5.8.4.2 ESTABLISHMENT OF SEZS/INDUSTRIAL PARKS

6 REGULATION COVERAGE

6.1 PRODUCT CODES

6.2 CERTIFIED STANDARDS

6.3 SAFETY STANDARDS

6.3.1 MATERIAL HANDLING & STORAGE

6.3.2 TRANSPORT & PRECAUTIONS

6.3.3 HAZARD IDENTIFICATION

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISE IN GASTROINTESTINAL BLEEDING CASES

7.1.2 AGING POPULATION DRIVING INCREASED DEMAND FOR GI DISORDERS

7.1.3 ADOPTION OF MINIMALLY INVASIVE ENDOSCOPIC PROCEDURES

7.1.4 RISING AWARENESS AND EXPANDED SCREENING PROGRAMS FOR GASTROINTESTINAL ENDOSCOPY

7.2 RESTRAINTS

7.2.1 HIGH COST AND TECHNICAL COMPLEXITY OF ENDOSCOPIC HEMOSTASIS DEVICES

7.2.2 LIMITED AWARENESS IN LOW-INCOME COUNTRIES

7.3 OPPORTUNITIES

7.3.1 TECHNOLOGICAL ADVANCEMENTS IN HEMOSTASIS DEVICES

7.3.2 EXPANSION IN EMERGING MARKETS (ASIA-PACIFIC, LATIN AMERICA)

7.3.3 GROWING ADOPTION OF HOME-BASED AND CAPSULE ENDOSCOPY SOLUTIONS

7.4 CHALLENGES

7.4.1 REIMBURSEMENT ISSUES FOR ENDOSCOPIC PROCEDURES

7.4.2 COMPLEXITIES IN ENDOSCOPE REPROCESSING AND STERILIZATION PROCESSES

8 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE

8.1 OVERVIEW

8.2 MECHANICAL HEMOSTASIS DEVICES

8.2.1 MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE

8.2.1.1 HEMOSTATIC CLIPS

8.2.1.1.1 HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE

8.2.1.1.1.1 THROUGH-THE-SCOPE (TTS) CLIPS

8.2.1.1.1.2 OVER-THE-SCOPE (OTS) CLIPS

8.2.1.1.2 HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL

8.2.1.1.2.1 STAINLESS STEEL

8.2.1.1.2.2 TITANIUM

8.2.1.2 BANDING DEVICES

8.2.1.2.1 BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE

8.2.1.2.1.1 VARICEAL BANDING KITS

8.2.1.2.1.2 OESOPHAGEAL BANDING DEVICES

8.2.1.3 HEMOSTATIC FORCEPS

8.2.1.4 OTHERS

8.2.2 MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

8.2.2.1 NORTH AMERICA

8.2.2.2 EUROPE

8.2.2.3 ASIA-PACIFIC

8.2.2.4 SOUTH AMERICA

8.2.2.5 MIDDLE EAST & AFRICA

8.3 THERMAL DEVICES

8.3.1 THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE

8.3.1.1 ARGON PLASMA COAGULATORS

8.3.1.2 HEATER PROBES

8.3.1.3 BIPOLAR COAGULATION DEVICES

8.3.1.3.1 BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE

8.3.1.3.1.1 MONOPOLAR

8.3.1.3.1.2 BIPOLAR

8.3.1.3.2 BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION

8.3.1.3.2.1 UPPER GI BLEEDING

8.3.1.3.2.2 LOWER GI BLEEDING

8.3.1.4 OTHERS

8.3.2 THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

8.3.2.1 NORTH AMERICA

8.3.2.2 EUROPE

8.3.2.3 ASIA-PACIFIC

8.3.2.4 SOUTH AMERICA

8.3.2.5 MIDDLE EAST & AFRICA

8.4 TOPICAL AGENTS AND INJECTABLES

8.4.1 TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE

8.4.1.1 EPINEPHRINE INJECTION

8.4.1.2 HEMOSTATIC SPRAY (POWDER)

8.4.1.3 HEMOSTATIC GELS

8.4.1.4 FIBRIN SEALANTS

8.4.1.5 SCLEROSING AGENTS

8.4.2 TOPICAL AGENTS AND INJECTABLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

8.4.2.1 NORTH AMERICA

8.4.2.2 EUROPE

8.4.2.3 ASIA-PACIFIC

8.4.2.4 SOUTH AMERICA

8.4.2.5 MIDDLE EAST & AFRICA

8.5 OTHERS

8.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

8.5.1.1 NORTH AMERICA

8.5.1.2 EUROPE

8.5.1.3 ASIA-PACIFIC

8.5.1.4 SOUTH AMERICA

8.5.1.5 MIDDLE EAST & AFRICA

9 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE TYPE

9.1 OVERVIEW

9.2 UPPER GASTROINTESTINAL ENDOSCOPY

9.2.1 UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE

9.2.1.1 BLEEDING ULCER MANAGEMENT

9.2.1.2 VARICEAL BLEEDING

9.2.1.3 DIEULAFOY LESION

9.2.2 UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

9.2.2.1 NORTH AMERICA

9.2.2.2 EUROPE

9.2.2.3 ASIA-PACIFIC

9.2.2.4 SOUTH AMERICA

9.2.2.5 MIDDLE EAST & AFRICA

9.3 LOWER GASTROINTESTINAL ENDOSCOPY

9.3.1 LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE

9.3.1.1 COLONIC BLEEDING

9.3.1.2 DIVERTICULAR BLEEDING

9.3.2 LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

9.3.2.1 NORTH AMERICA

9.3.2.2 EUROPE

9.3.2.3 ASIA-PACIFIC

9.3.2.4 SOUTH AMERICA

9.3.2.5 MIDDLE EAST & AFRICA

9.4 BRONCHOSCOPIC HEMOSTASIS

9.4.1 BRONCHOSCOPIC HEMOSTASIS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

9.4.1.1 NORTH AMERICA

9.4.1.2 EUROPE

9.4.1.3 ASIA-PACIFIC

9.4.1.4 SOUTH AMERICA

9.4.1.5 MIDDLE EAST & AFRICA

9.5 OTHERS

9.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

9.5.1.1 NORTH AMERICA

9.5.1.2 EUROPE

9.5.1.3 ASIA-PACIFIC

9.5.1.4 SOUTH AMERICA

9.5.1.5 MIDDLE EAST & AFRICA

10 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION

10.1 OVERVIEW

10.2 GASTROINTESTINAL BLEEDING

10.2.1 GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE

10.2.1.1 PEPTIC ULCER BLEEDING

10.2.1.2 ESOPHAGEAL VARICES

10.2.1.3 COLORECTAL CANCERS

10.2.2 GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE

10.2.2.1 MECHANICAL HEMOSTASIS DEVICES

10.2.2.2 THERMAL DEVICES

10.2.2.3 TOPICAL AGENTS AND INJECTABLES

10.2.2.4 OTHERS

10.2.3 GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

10.2.3.1 NORTH AMERICA

10.2.3.2 EUROPE

10.2.3.3 ASIA-PACIFIC

10.2.3.4 SOUTH AMERICA

10.2.3.5 MIDDLE EAST & AFRICA

10.3 NON-GASTROINTESTINAL BLEEDING

10.3.1 NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE

10.3.1.1 NASAL BLEEDING (EPISTAXIS)

10.3.1.2 POST-SURGICAL BLEEDING

10.3.2 NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE

10.3.2.1 MECHANICAL HEMOSTASIS DEVICES

10.3.2.2 THERMAL DEVICES

10.3.2.3 TOPICAL AGENTS & INJECTABLES

10.3.2.4 OTHERS

10.3.3 NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.3.3.1 NORTH AMERICA

10.3.3.2 EUROPE

10.3.3.3 ASIA-PACIFIC

10.3.3.4 SOUTH AMERICA

10.3.3.5 MIDDLE EAST & AFRICA

10.4 TRAUMA MANAGEMENT

10.4.1 TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE

10.4.1.1 MECHANICAL HEMOSTASIS DEVICES

10.4.1.2 THERMAL DEVICES

10.4.1.3 TOPICAL AGENTS & INJECTABLES

10.4.1.4 OTHERS

10.4.2 TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

10.4.2.1 NORTH AMERICA

10.4.2.2 EUROPE

10.4.2.3 ASIA-PACIFIC

10.4.2.4 SOUTH AMERICA

10.4.2.5 MIDDLE EAST & AFRICA

10.5 OTHERS

10.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

10.5.1.1 NORTH AMERICA

10.5.1.2 EUROPE

10.5.1.3 ASIA-PACIFIC

10.5.1.4 SOUTH AMERICA

10.5.1.5 MIDDLE EAST & AFRICA

11 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.2.1 HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE

11.2.1.1 PUBLIC

11.2.1.2 PRIVATE

11.2.2 HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

11.2.2.1 NORTH AMERICA

11.2.2.2 EUROPE

11.2.2.3 ASIA-PACIFIC

11.2.2.4 SOUTH AMERICA

11.2.2.5 MIDDLE EAST & AFRICA

11.3 AMBULATORY SURGERY CENTERS

11.3.1 AMBULATORY SURGERY CENTERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

11.3.1.1 NORTH AMERICA

11.3.1.2 EUROPE

11.3.1.3 ASIA-PACIFIC

11.3.1.4 SOUTH AMERICA

11.3.1.5 MIDDLE EAST & AFRICA

11.4 SPECIALTY CLINICS

11.4.1 SPECIALTY CLINICS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

11.4.1.1 NORTH AMERICA

11.4.1.2 EUROPE

11.4.1.3 ASIA-PACIFIC

11.4.1.4 SOUTH AMERICA

11.4.1.5 MIDDLE EAST & AFRICA

11.5 OTHERS

11.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

11.5.1.1 NORTH AMERICA

11.5.1.2 EUROPE

11.5.1.3 ASIA-PACIFIC

11.5.1.4 SOUTH AMERICA

11.5.1.5 MIDDLE EAST & AFRICA

12 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 INDIRECT SALES

12.2.1 INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE

12.2.1.1 OFFLINE

12.2.1.2 ONLINE

12.2.2 INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

12.2.2.1 NORTH AMERICA

12.2.2.2 EUROPE

12.2.2.3 ASIA-PACIFIC

12.2.2.4 SOUTH AMERICA

12.2.2.5 MIDDLE EAST & AFRICA

12.3 DIRECT SALES

12.3.1 DIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

12.3.1.1 NORTH AMERICA

12.3.1.2 EUROPE

12.3.1.3 ASIA-PACIFIC

12.3.1.4 SOUTH AMERICA

12.3.1.5 MIDDLE EAST & AFRICA

13 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY REGION

13.1 EUROPE

13.1.1 GERMANY

13.1.2 U.K.

13.1.3 FRANCE

13.1.4 ITALY

13.1.5 SPAIN

13.1.6 NETHERLANDS

13.1.7 BELGIUM

13.1.8 SWITZERLAND

13.1.9 SWEDEN

13.1.10 DENMARK

13.1.11 NORWAY

13.1.12 FINLAND

13.1.13 RUSSIA

13.1.14 TURKEY

13.1.15 REST OF EUROPE

14 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: GLOBAL

15 SWOT ANALYSIS

16 COMPANY PROFILES MANUFACTURERS

16.1 OLYMPUS CORPORATION

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENT

16.2 BOSTON SCIENTIFIC CORPORATION

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 CONMED CORPORATION

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENT

16.4 MEDTRONIC

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENT

16.5 COOK

16.5.1 COMPANY SNAPSHOT

16.5.2 COMPANY SHARE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENT

16.6 ANKAFERD

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVEOPMENT

16.7 B. BRAUN SE

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVEOPMENT

16.8 CREO MEDICAL GMBH

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 DIVERSATEK, INC.

16.9.1 COMPANY SNAPSHOT

16.9.2 PRODUCT PORTFOLIO

16.9.3 RECENT DEVEOPMENT

16.1 DUOMED GROUP

16.10.1 COMPANY SNAPSHOT

16.10.2 PRODUCT PORTFOLIO

16.10.3 RECENT DEVEOPMENT

16.11 ENDOCLOT PLUS, INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVEOPMENT

16.12 ERBE ELEKTROMEDIZIN GMBH

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENT

16.13 FUJIFILM HOLDINGS CORPORATION

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENT

16.14 JOHNSON & JOHNSON (ETHICON)

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVEOPMENT

16.15 KARL STORZ SE & CO. KG, TUTTLINGEN

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVEOPMENT

16.16 MEDITALIA S.R.L.

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENT

16.17 MICRO-TECH ENDOSCOPY

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENT

16.18 MTW ENDOSKOPIE MANUFAKTU

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVEOPMENT

16.19 OVESCO ENDOSCOPY AG

16.19.1 COMPANY SNAPSHOT

16.19.2 PRODUCT PORTFOLIO

16.19.3 RECENT DEVEOPMENT

16.2 PENTAX MEDICAL

16.20.1 COMPANY SNAPSHOT

16.20.2 SOLUTION PORTFOLIO

16.20.3 RECENT DEVELOPMENT

16.21 STERIS

16.21.1 COMPANY SNAPSHOT

16.21.2 REVENUE ANALYSIS

16.21.3 PRODUCT PORTFOLIO

16.21.4 RECENT DEVELOPMENT

17 COMPANY PROFILES DISTRIBUTOR

17.1 BOSTON IVY HEALTHCARE SOLUTIONS PRIVATE LIMITED

17.1.1 COMPANY SNAPSHOT

17.1.2 PRODUCT PORTFOLIO

17.1.3 RECENT DEVELOPMENT

17.2 CARDINAL HEALTH

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 PRODUCT PORTFOLIO

17.2.4 RECENT DEVEOPMENT

17.3 HENRY SCHEIN, INC.

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 PRODUCT PORTFOLIO

17.3.4 RECENT DEVEOPMENT

17.4 MCKESSON MEDICAL-SURGICAL INC.

17.4.1 COMPANY SNAPSHOT

17.4.2 PRODUCT PORTFOLIO

17.4.3 RECENT DEVEOPMENT

17.5 MFI MEDICAL

17.5.1 COMPANY SNAPSHOT

17.5.2 PRODUCT PORTFOLIO

17.5.3 RECENT DEVEOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

Список таблиц

TABLE 1 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2 EUROPE MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 3 EUROPE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 4 EUROPE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 5 EUROPE BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 6 EUROPE MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 7 EUROPE THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 8 EUROPE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 9 EUROPE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 10 EUROPE THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 11 EUROPE TOPICAL AGENTS & INJECTABLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 12 EUROPE TOPICAL AGENTS AND INJECTABLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 13 EUROPE OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 14 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 15 EUROPE UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 16 EUROPE UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 17 EUROPE LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 18 EUROPE LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 19 EUROPE BRONCHOSCOPIC HEMOSTASIS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 20 EUROPE OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 21 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 22 EUROPE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 23 EUROPE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 24 EUROPE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 25 EUROPE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 26 EUROPE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 27 EUROPE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 28 EUROPE TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 29 EUROPE TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 30 EUROPE OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 31 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 32 EUROPE HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 33 EUROPE HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 34 EUROPE AMBULATORY SURGERY CENTERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 35 EUROPE SPECIALTY CLINICS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 36 EUROPE OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 37 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 38 EUROPE INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 39 EUROPE INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 40 EUROPE DIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 41 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)

TABLE 42 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 43 EUROPE MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 44 EUROPE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 45 EUROPE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 46 EUROPE BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 47 EUROPE THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 48 EUROPE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 49 EUROPE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 50 EUROPE TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 51 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 52 EUROPE UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 53 EUROPE LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 54 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 55 EUROPE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 56 EUROPE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 57 EUROPE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 58 EUROPE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 59 EUROPE TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 60 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 61 EUROPE HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 62 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 63 EUROPE INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 64 GERMANY ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 65 GERMANY MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 66 GERMANY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 67 GERMANY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 68 GERMANY BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 69 GERMANY THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 70 GERMANY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 71 GERMANY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 72 GERMANY TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 73 GERMANY ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 74 GERMANY UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 75 GERMANY LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 76 GERMANY ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 77 GERMANY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 78 GERMANY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 79 GERMANY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 80 GERMANY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 81 GERMANY TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 82 GERMANY ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 83 GERMANY HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 84 GERMANY ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 85 GERMANY INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 86 U.K. ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 87 U.K. MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 88 U.K. HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 89 U.K. HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 90 U.K. BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 91 U.K. THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 92 U.K. BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 93 U.K. BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 94 U.K. TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 95 U.K. ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 96 U.K. UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 97 U.K. LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 98 U.K. ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 99 U.K. GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 100 U.K. GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 101 U.K. NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 102 U.K. NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 103 U.K. TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 104 U.K. ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 105 U.K. HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 106 U.K. ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 107 U.K. INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 108 FRANCE ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 109 FRANCE MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 110 FRANCE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 111 FRANCE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 112 FRANCE BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 113 FRANCE THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 114 FRANCE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 115 FRANCE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 116 FRANCE TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 117 FRANCE ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 118 FRANCE UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 119 FRANCE LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 120 FRANCE ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 121 FRANCE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 122 FRANCE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 123 FRANCE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 124 FRANCE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 125 FRANCE TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 126 FRANCE ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 127 FRANCE HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 128 FRANCE ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 129 FRANCE INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 130 ITALY ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 131 ITALY MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 132 ITALY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 133 ITALY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 134 ITALY BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 135 ITALY THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 136 ITALY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 137 ITALY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 138 ITALY TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 139 ITALY ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 140 ITALY UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 141 ITALY LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 142 ITALY ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 143 ITALY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 144 ITALY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 145 ITALY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 146 ITALY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 147 ITALY TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 148 ITALY ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 149 ITALY HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 150 ITALY ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 151 ITALY INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 152 SPAIN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 153 SPAIN MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 154 SPAIN HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 155 SPAIN HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 156 SPAIN BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 157 SPAIN THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 158 SPAIN BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 159 SPAIN BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 160 SPAIN TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 161 SPAIN ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 162 SPAIN UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 163 SPAIN LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 164 SPAIN ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 165 SPAIN GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 166 SPAIN GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 167 SPAIN NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 168 SPAIN NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 169 SPAIN TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 170 SPAIN ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 171 SPAIN HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 172 SPAIN ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 173 SPAIN INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 174 NETHERLANDS ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 175 NETHERLANDS MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 176 NETHERLANDS HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 177 NETHERLANDS HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 178 NETHERLANDS BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 179 NETHERLANDS THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 180 NETHERLANDS BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 181 NETHERLANDS BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 182 NETHERLANDS TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 183 NETHERLANDS ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 184 NETHERLANDS UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 185 NETHERLANDS LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 186 NETHERLANDS ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 187 NETHERLANDS GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 188 NETHERLANDS GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 189 NETHERLANDS NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 190 NETHERLANDS NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 191 NETHERLANDS TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 192 NETHERLANDS ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 193 NETHERLANDS HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 194 NETHERLANDS ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 195 NETHERLANDS INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 196 BELGIUM ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 197 BELGIUM MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 198 BELGIUM HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 199 BELGIUM HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 200 BELGIUM BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 201 BELGIUM THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 202 BELGIUM BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 203 BELGIUM BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 204 BELGIUM TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 205 BELGIUM ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 206 BELGIUM UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 207 BELGIUM LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 208 BELGIUM ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 209 BELGIUM GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 210 BELGIUM GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 211 BELGIUM NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 212 BELGIUM NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 213 BELGIUM TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 214 BELGIUM ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 215 BELGIUM HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 216 BELGIUM ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 217 BELGIUM INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 218 SWITZERLAND ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 219 SWITZERLAND MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 220 SWITZERLAND HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 221 SWITZERLAND HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 222 SWITZERLAND BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 223 SWITZERLAND THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 224 SWITZERLAND BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 225 SWITZERLAND BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 226 SWITZERLAND TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 227 SWITZERLAND ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 228 SWITZERLAND UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 229 SWITZERLAND LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 230 SWITZERLAND ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 231 SWITZERLAND GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 232 SWITZERLAND GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 233 SWITZERLAND NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 234 SWITZERLAND NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 235 SWITZERLAND TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 236 SWITZERLAND ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 237 SWITZERLAND HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 238 SWITZERLAND ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 239 SWITZERLAND INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 240 SWEDEN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 241 SWEDEN MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 242 SWEDEN HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 243 SWEDEN HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 244 SWEDEN BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 245 SWEDEN THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 246 SWEDEN BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 247 SWEDEN BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 248 SWEDEN TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 249 SWEDEN ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 250 SWEDEN UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 251 SWEDEN LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 252 SWEDEN ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 253 SWEDEN GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 254 SWEDEN GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 255 SWEDEN NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 256 SWEDEN NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 257 SWEDEN TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 258 SWEDEN ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 259 SWEDEN HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 260 SWEDEN ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 261 SWEDEN INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 262 DENMARK ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 263 DENMARK MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 264 DENMARK HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 265 DENMARK HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 266 DENMARK BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 267 DENMARK THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 268 DENMARK BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 269 DENMARK BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 270 DENMARK TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 271 DENMARK ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 272 DENMARK UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 273 DENMARK LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 274 DENMARK ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 275 DENMARK GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 276 DENMARK GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 277 DENMARK NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 278 DENMARK NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 279 DENMARK TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 280 DENMARK ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 281 DENMARK HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 282 DENMARK ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 283 DENMARK INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 284 NORWAY ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 285 NORWAY MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 286 NORWAY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 287 NORWAY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 288 NORWAY BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 289 NORWAY THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 290 NORWAY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 291 NORWAY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 292 NORWAY TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 293 NORWAY ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 294 NORWAY UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 295 NORWAY LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 296 NORWAY ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 297 NORWAY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 298 NORWAY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 299 NORWAY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 300 NORWAY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 301 NORWAY TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 302 NORWAY ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 303 NORWAY HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 304 NORWAY ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 305 NORWAY INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 306 FINLAND ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 307 FINLAND MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 308 FINLAND HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 309 FINLAND HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 310 FINLAND BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 311 FINLAND THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 312 FINLAND BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 313 FINLAND BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 314 FINLAND TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 315 FINLAND ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 316 FINLAND UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 317 FINLAND LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 318 FINLAND ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 319 FINLAND GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 320 FINLAND GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 321 FINLAND NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 322 FINLAND NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 323 FINLAND TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 324 FINLAND ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 325 FINLAND HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 326 FINLAND ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 327 FINLAND INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 328 RUSSIA ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 329 RUSSIA MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 330 RUSSIA HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 331 RUSSIA HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 332 RUSSIA BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 333 RUSSIA THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 334 RUSSIA BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 335 RUSSIA BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 336 RUSSIA TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 337 RUSSIA ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 338 RUSSIA UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 339 RUSSIA LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 340 RUSSIA ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 341 RUSSIA GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 342 RUSSIA GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 343 RUSSIA NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 344 RUSSIA NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 345 RUSSIA TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 346 RUSSIA ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 347 RUSSIA HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 348 RUSSIA ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 349 RUSSIA INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 350 TURKEY ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 351 TURKEY MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 352 TURKEY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 353 TURKEY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 354 TURKEY BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 355 TURKEY THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 356 TURKEY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 357 TURKEY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 358 TURKEY TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 359 TURKEY ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 360 TURKEY UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 361 TURKEY LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 362 TURKEY ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 363 TURKEY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 364 TURKEY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 365 TURKEY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 366 TURKEY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 367 TURKEY TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 368 TURKEY ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 369 TURKEY HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 370 TURKEY ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 371 TURKEY INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 372 REST OF EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 373 REST OF EUROPE MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 374 REST OF EUROPE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 375 REST OF EUROPE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)

TABLE 376 REST OF EUROPE BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 377 REST OF EUROPE THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 378 REST OF EUROPE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)

TABLE 379 REST OF EUROPE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 380 REST OF EUROPE TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 381 REST OF EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)

TABLE 382 REST OF EUROPE UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 383 REST OF EUROPE LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 384 REST OF EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 385 REST OF EUROPE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 386 REST OF EUROPE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 387 REST OF EUROPE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 388 REST OF EUROPE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 389 REST OF EUROPE TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 390 REST OF EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 391 REST OF EUROPE HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 392 REST OF EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 393 REST OF EUROPE INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)

 

Список рисунков

FIGURE 1 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: SEGMENTATION

FIGURE 2 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: COUNTRYWISE MARKET ANALYSIS

FIGURE 5 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: MULTIVARIATE MODELLING

FIGURE 8 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: MARKET END-USER COVERAGE GRID

FIGURE 11 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: SEGMENTATION

FIGURE 12 TWO SEGMENTS COMPRISE THE DOMINICAN REPUBLIC ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE

FIGURE 13 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: EXECUTIVE SUMMARY

FIGURE 14 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: STRATEGIC DECISIONS

FIGURE 15 RISING PREVALANCE OF ENDOSCOPIC HEMOSTASIS CASES EXPECTED TO DRIVE THE GROWTH OF THE EUROPE ENDOSCOPIC HEMOSTASIS MARKET FROM 2026 TO 2033

FIGURE 16 THE TYPE 2 ENDOSCOPIC HEMOSTASIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ENDOSCOPIC HEMOSTASIS MARKET IN 2026 & 2033

FIGURE 17 COMPANY EVALUATION QUADRANT

FIGURE 18 DROC ANALYSIS

FIGURE 19 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2025

FIGURE 20 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY PRODUCT TYPE , CAGR (2025-2032)

FIGURE 21 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY PRODUCT TYPE , CAGR (2025-2032)

FIGURE 22 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY PRODUCT TYPE , LIFELINE CURVE (2025-2032)

FIGURE 23 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE TYPE, 2025

FIGURE 24 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY PROCEDURE , 2026-2033 (USD THOUSAND)

FIGURE 25 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY PROCEDURE , 2026-2033 (USD THOUSAND)

FIGURE 26 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2025

FIGURE 27 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY APPLICATION, 2026-2033 (USD THOUSAND)

FIGURE 28 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY APPLICATION, 2026-2033 (USD THOUSAND)

FIGURE 29 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY APPLICATION, 2026-2033 (USD THOUSAND)

FIGURE 30 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2025

FIGURE 31 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY END USER, 2026-2033 (USD THOUSAND)

FIGURE 32 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY END USER, 2026-2033 (USD THOUSAND)

FIGURE 33 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY END USER, 2026-2033 (USD THOUSAND)

FIGURE 34 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2025

FIGURE 35 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY DISTRIBUTION CHANNEL, 2026-2033 (USD THOUSAND)

FIGURE 36 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY DISTRIBUTION CHANNEL, 2026-2033 (USD THOUSAND)

FIGURE 37 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY DISTRIBUTION CHANNEL, 2026-2033 (USD THOUSAND)

FIGURE 38 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: SNAPSHOT (2025)

FIGURE 39 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: COMPANY SHARE 2025 (%)

 

View Detailed Information Right Arrow

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

Европейский рынок эндоскопического гемостаза в 2025 году оценивался в 675,69 млн долларов.
Рынок эндоскопического гемостаза в Европе, по прогнозам, будет расти с устойчивыми ежегодными темпами роста (CAGR) в 7,7% во время рынка одноразовых пылевых масок, прогнозируется в период с 2026 по 2033 год.
Европейский рынок эндоскопического гемостаза разделен на пять заметных сегментов на основе типа продукта, процедуры, приложения, конечного пользователя и канала распространения. На основе типа продукта рынок сегментирован на механические устройства гемостаза, тепловые устройства, актуальные агенты и инъекционные и другие. На основе процедуры рынок сегментирован на верхнюю желудочно-кишечную эндоскопию, нижнюю желудочно-кишечную эндоскопию, бронхоскопический гемостаз и другие. На основе применения рынок сегментирован на желудочно-кишечные кровотечения, не желудочно-кишечные кровотечения, управление травмами и другие. На базе конечного потребителя рынок сегментирован на больницы, центры амбулаторной хирургии, специализированные клиники и другие. На основе канала распределения рынок сегментируется на прямые продажи и косвенные продажи.
Olympus Corporation (Япония), Boston Scientific Corporation (США), CONMED Corporation (США), Medtronic (Ирландия), Cook Medical (США) и другие.
Германия, Великобритания, Франция, Италия, Испания, Нидерланды, Бельгия, Швейцария, Швеция, Дания, Норвегия, Финляндия, Россия, Турция и остальная Европа.
Немецкий рынок эндоскопического гемостаза набирает обороты благодаря большому объему желудочно-кишечных эндоскопических процедур и раннему внедрению передовых методов терапевтической эндоскопии. Немецкие больницы и специализированные клиники уделяют большое внимание клинической точности, процедурной надежности и выбору устройств на основе фактических данных, что обеспечивает постоянный спрос на высокопроизводительные механические и энергетические гемостазы. Кроме того, наличие ведущих производителей медицинских изделий, хорошо зарекомендовавших себя программ клинической подготовки, а также строгих нормативных требований и стандартов качества способствует быстрому внедрению технологически совершенных устройств гемостаза. Ориентация Германии на процедурную стандартизацию, безопасность пациентов и оптимизацию результатов укрепляет ее позиции на европейском рынке, ориентированном на технологии и инновации.
Ожидается, что в течение прогнозируемого периода Дания станет свидетелем самого высокого CAGR на рынке эндоскопического гемостаза в Европе. Этот рост обусловлен передовой инфраструктурой здравоохранения страны, высоким внедрением минимально инвазивных эндоскопических процедур и увеличением распространенности желудочно-кишечных кровотечений.
Растущий потребительский сдвиг в сторону низкокалорийных, без сахара и безалкогольных функциональных напитков; Премиумизация хмелевой воды за счет уникальных сортов хмеля, минималистских составов и высококлассного позиционирования бренда, а также повышение внимания к устойчивым форматам упаковки, таким как перерабатываемые алюминиевые банки и цепочки поставок с низким содержанием углерода, и инновации продукта за счет новых сортов хмеля, уровней карбонизации и составов с чистой маркировкой с устойчивой упаковкой.
Testimonial